🇺🇸 FDA
Pipeline program

Norovirus GI.1/GII.4 Bivalent VLP Vaccine

NOR-204

Phase 2 mab completed

Quick answer

Norovirus GI.1/GII.4 Bivalent VLP Vaccine for Norovirus is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Norovirus
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials